183 related articles for article (PubMed ID: 26546142)
21. Effects of Exercise Training With and Without Ranolazine on Peak Oxygen Consumption, Daily Physical Activity, and Quality of Life in Patients With Chronic Stable Angina Pectoris.
Willis LH; Slentz CA; Johnson JL; Kelly LS; Craig KP; Hoselton AL; Kraus WE
Am J Cardiol; 2019 Sep; 124(5):655-660. PubMed ID: 31296368
[TBL] [Abstract][Full Text] [Related]
22. Ranolazine in treatment of stable angina in woman with atrial fibrillation and intermittent left bundle branch block - a case report.
Yuriivna Osovska N; Vitaliivna Kuzminova N
Pol Merkur Lekarski; 2016 Dec; 41(246):287-292. PubMed ID: 28024133
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness analysis of percutaneous coronary intervention for single-vessel coronary artery disease: an economic evaluation of the ORBITA trial.
McCreanor V; Nowbar A; Rajkumar C; Barnett AG; Francis D; Graves N; Boden WE; Weintraub WS; Al-Lamee R; Parsonage WA
BMJ Open; 2021 Feb; 11(2):e044054. PubMed ID: 33563623
[TBL] [Abstract][Full Text] [Related]
24. Ranolazine: impact on quality of life in patients with stable angina pectoris, results from an observational study in Austria - the ARETHA AT study.
Zweiker R; Aichinger J; Metzler B; Lang I; Wallner E; Delle-Karth G
Wien Klin Wochenschr; 2019 Apr; 131(7-8):165-173. PubMed ID: 30963332
[TBL] [Abstract][Full Text] [Related]
25. Clinical experience with ranolazine in a veteran population with chronic stable angina.
Reeder DN; Gillette MA; Franck AJ; Frohnapple DJ
Ann Pharmacother; 2012 Jan; 46(1):42-50. PubMed ID: 22215689
[TBL] [Abstract][Full Text] [Related]
26. Cost-utility of ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Spain.
Hidalgo-Vega A; Ramos-Goñi JM; Villoro R
Eur J Health Econ; 2014 Dec; 15(9):917-25. PubMed ID: 24122303
[TBL] [Abstract][Full Text] [Related]
27. Impact of ranolazine on coronary microvascular dysfunction (MICRO) study.
Ahmed B; Mondragon J; Sheldon M; Clegg S
Cardiovasc Revasc Med; 2017 Sep; 18(6):431-435. PubMed ID: 28576663
[TBL] [Abstract][Full Text] [Related]
28. New Anti-Anginal Drugs: Ranolazine.
Cavallino C; Facchini M; Veia A; Bacchni S; Rosso R; Rognoni A; Rametta F; Lupi A; Bongo AS
Cardiovasc Hematol Agents Med Chem; 2015; 13(1):14-20. PubMed ID: 25544118
[TBL] [Abstract][Full Text] [Related]
29. Update on evidence for treatment with ranolazine in stable angina.
Carbone F; Montecucco F; Mach F
Swiss Med Wkly; 2013; 143():w13874. PubMed ID: 24163124
[TBL] [Abstract][Full Text] [Related]
30. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.
Chaitman BR; Pepine CJ; Parker JO; Skopal J; Chumakova G; Kuch J; Wang W; Skettino SL; Wolff AA;
JAMA; 2004 Jan; 291(3):309-16. PubMed ID: 14734593
[TBL] [Abstract][Full Text] [Related]
31. Ranolazine: effects on ischemic heart.
Rognoni A; Barbieri L; Cavallino C; Bacchini S; Veia A; Degiovanni A; Rametta F; Nardi F; Lazzero M; Lupi A; Bongo AS
Recent Pat Cardiovasc Drug Discov; 2013 Dec; 8(3):197-203. PubMed ID: 23961914
[TBL] [Abstract][Full Text] [Related]
32. Effects of ranolazine on various outcomes in patients with stable angina: an updated meta-analysis.
Manolis A; Kallistratos M; Poulimenos L; Zamfir T; Thomopoulos C
Hellenic J Cardiol; 2023; 71():26-32. PubMed ID: 36481415
[TBL] [Abstract][Full Text] [Related]
33. Economic evaluation of ivabradine in the treatment of chronic heart failure in Greece.
Kourlaba G; Parissis J; Karavidas A; Beletsi A; Milonas C; Branscombe N; Maniadakis N
BMC Health Serv Res; 2014 Dec; 14():631. PubMed ID: 25496716
[TBL] [Abstract][Full Text] [Related]
34. Revascularization Rates and Associated Costs in Patients With Stable Ischemic Heart Disease Initiating Ranolazine Versus Traditional Antianginals as Add-on Therapy.
Meyer N; Tran O; Hartsfield C; Nguyen L; Kazi DS; Koch B
Am J Cardiol; 2019 May; 123(10):1602-1609. PubMed ID: 30832963
[TBL] [Abstract][Full Text] [Related]
35. Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK.
Diamantopoulos A; Finckh A; Huizinga T; Sungher DK; Sawyer L; Neto D; Dejonckheere F
Pharmacoeconomics; 2014 Aug; 32(8):775-87. PubMed ID: 24854959
[TBL] [Abstract][Full Text] [Related]
36. Impact of ranolazine on clinical outcomes and healthcare resource utilization in patients with refractory angina pectoris.
Ling H; Packard KA; Burns TL; Hilleman DE
Am J Cardiovasc Drugs; 2013 Dec; 13(6):407-12. PubMed ID: 23873327
[TBL] [Abstract][Full Text] [Related]
37. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
38. Effects of ranolazine on exercise tolerance and angina frequency in patients with severe chronic angina receiving maximally-tolerated background therapy: analysis from the Combination Assessment of Ranolazine In Stable Angina (CARISA) randomized trial.
Sendón JL; Lee S; Cheng ML; Ben-Yehuda O;
Eur J Prev Cardiol; 2012 Oct; 19(5):952-9. PubMed ID: 22689417
[TBL] [Abstract][Full Text] [Related]
39. Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial.
Weisz G; Généreux P; Iñiguez A; Zurakowski A; Shechter M; Alexander KP; Dressler O; Osmukhina A; James S; Ohman EM; Ben-Yehuda O; Farzaneh-Far R; Stone GW;
Lancet; 2016 Jan; 387(10014):136-45. PubMed ID: 26474810
[TBL] [Abstract][Full Text] [Related]
40. Ranolazine Reduces Angina in Women with Ischemic Heart Disease: Results of an Open-Label, Multicenter Trial.
Mehta PK; Sharma S; Minissian M; Harsch MR; Martinson M; Nyman JA; Shaw LJ; Bairey Merz CN; Wenger NK
J Womens Health (Larchmt); 2019 May; 28(5):573-582. PubMed ID: 30888919
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
